Maryland Heights, MO, February 27, 2017 --(PR.com
)-- The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market is estimated to reach nearly USD 11.2 Billion in 2020, expanding at a CAGR of 8.6% from 2016 to 2020.
Browse Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Market by Geography North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and Forecast 2016-2020 at https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/.
Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a novel therapy for the treatment of hypervascuarized tumours. Through the intra-arterial delivery of microspheres, DEB-TACE allows for embolization as well as local release of chemotherapy in the treatment of hepatic malignancy, providing an alternative therapeutic option in unresectable tumours. Drug-eluting bead TACE is becoming more widely utilized in primary and liver-dominant metastatic disease of the liver. Microcatheters, are thin wall, small diameter catheters and delivery devices used in minimally invasive applications. These small catheters are ideal for navigating the vast network of tiny veins found within the body. Microcatheters are employed extensively in the neurovascular and cardiovascular fields. They are most commonly used in small vessel or selective diagnostic and interventional procedures, where an application requires an ultra-thin device for delivery, diagnosis, or mapping, a microcatheter is used. Radiopaque beads provide a practical solution for real time display of embolic material or drug delivery. These beads provide better conspicuity in determining the target during embolization and also allow optimal balance and delivery performance.
The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report estimates the market size (Revenue USD million – 2013 to 2020) by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2016 to 2020). The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating the global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market and profiled in this report include Abbott Laboratories (Abbott EP), ABK Biomedical, Inc., Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Medtronic, Inc., Merit Medical Systems, Inc., Stryker Corporation, Surefire Medical, Inc., Terumo Corporation, and Vascular Solutions, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043